CEACAM5 and gastric adenocarcinoma: The expression of CEACAM5 plays a critical role in both gastric adenoma and early gastric cancer, with a positivity rate of approximately 34–66% in early-stage gastric adenocarcinomas [29,30,36,59], suggesting its potential utility for early diagnosis.